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ABSTRACT
Objectives: Data from the Intergroup Exemestane Study
(IES) suggest that switching to the aromatase inhibitor,
exemestane, after 2 to 3 years of tamoxifen therapy prolongs
disease-free survival versus continuing on tamoxifen therapy.
We sought to evaluate the cost-effectiveness of this manage-
ment strategy.
Methods: A Markov model was developed to predict
patients’ transitions across various health states based on
treatment strategy (continuing tamoxifen vs. switching to
exemestane), breast cancer status (no recurrence, local or
distant recurrence, contralateral breast cancer), and other
related health events (osteoporosis, endometrial cancer,
death). Rates of disease-related events (recurrence and con-
tralateral breast cancer) were estimated using data from the
IES. Survival and lifetime medical-care costs by type of
disease-related event were estimated using SEER-Medicare
data. The model was used to estimate direct costs (in 2004 US
dollars), life expectancy, quality-adjusted life-years (QALYs),
and incremental cost-effectiveness.
Results: Switching to exemestane versus continuing tamox-
ifen therapy was associated with increased disease-free sur-
vival (181 vs. 172 months), QALYs (12.21 vs. 11.89), and
net discounted lifetime costs of cancer care ($12,124 vs.
$7724 per patient). The incremental cost-effectiveness ratio
of exemestane was $20,100 per QALY gained (95% conﬁ-
dence interval: $12,100, $59,000). Sensitivity analyses
showed that results were robust to plausible variations in
recurrence rates, costs, and utilities.
Conclusions: Switching postmenopausal early-stage breast
cancer patients to exemestane after 2 to 3 years of tamoxifen
appears to be a cost-effective treatment strategy versus com-
pleting a 5-year course of tamoxifen.
Keywords: breast cancer, cost-effectiveness, decision analysis,
hormonal therapy.
Introduction
After ﬁrst being introduced in 1977 for the treatment
of advanced breast cancer, tamoxifen received Food
and Drug Administration approval in 1986 as adju-
vant therapy in postmenopausal women with early-
stage breast cancer [1]. Since that time, a 5-year
regimen of tamoxifen has been established as the stan-
dard adjuvant therapy for early-stage breast cancer [2].
Meta-analyses of large clinical trials of tamoxifen
suggest that this regimen reduces the annual breast
cancer mortality rate by 31% among women with
estrogen receptor (ER)-positive tumors [3].
Aromatase inhibitors—including anastrozole, letro-
zole, and exemestane—have recently been introduced
to adjuvant treatment for postmenopausal women
with hormone receptor-positive disease. Originally
approved for late-stage breast cancer, these drugs have
been evaluated in clinical trials as adjuvant therapy for
early-stage breast cancer under a variety of scenarios.
A 5-year course of aromatase inhibitor treatment
has been compared directly with the standard 5-year
regimen of tamoxifen [4,5]; a strategy involving
switching patients from tamoxifen to an aromatase
inhibitor midway through the 5-year tamoxifen
regimen has been compared with staying on tamoxifen
for the full 5 years [6,7]; and a 5-year course of aro-
matase inhibitor treatment after completion of the
5-year tamoxifen regimen has been evaluated in a
placebo-controlled trial [8].
The Intergroup Exemestane Study (IES) was the ﬁrst
trial to highlight the potential beneﬁts of switching
tamoxifen patients to an aromatase inhibitor midway
through the 5-year tamoxifen regimen; in this study,
switching to exemestane was associated with improved
disease-free survival compared with staying on tamox-
ifen [6]. Nevertheless, because exemestane is consider-
ably more expensive than tamoxifen, it remains
unknown whether the clinical beneﬁts are worth the
added cost of treatment. We accordingly performed
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an analysis of the cost-effectiveness of switching to
exemestane versus staying on tamoxifen based on the
IES data. Because the trial data span a limited period of
time and do not include information on resource uti-
lization, we used modeling techniques and data from
sources external to the IES to project long-term sur-
vival and economic costs.
Methods
Methodological Overview
We employed techniques of decision analysis to con-
struct and estimate a state-transition model of the
management, outcomes, and costs of early-stage breast
cancer. The model is composed of several distinct
health “states” of relevance to patients receiving adju-
vant hormonal therapy, deﬁned according to current
disease status (no recurrence, local or distant recur-
rence, contralateral breast cancer), other health events
related to hormone therapy (osteoporosis, endometrial
cancer), and survival (death from breast cancer, death
from other causes) (Fig. 1). Assigned to each health
state are measures of utility and economic cost. Esti-
mation of the model involves predicting and tracking
patients’ transitions (for convenience, in 6-month
intervals) across these health states in a Markov
process [9], and tallying their cumulative disease-free
survival time, life-years lived, utilities, and costs to the
end of the study period.
Patients entering the model are assumed to be
similar in characteristics to subjects enrolled in the
IES (e.g., ER-positive or ER-unknown, mean age of
64 years). The model predicts their risks of disease-
related events (recurrence and cancers in the contralat-
eral breast) over a 10-year period after the decision to
switch to exemestane or stay on tamoxifen. Because
the IES data available to us spanned a maximum of
48 months and did not include long-term survival or
medical-care costs after disease-related events, we had
to extrapolate the data out to 10 years and supplement
them with survival and cost data from the SEER-
Medicare program. In base-case analyses, we conser-
vatively assumed no difference between the two
treatment strategies in rates of disease-related events in
years 5 to 10, and we estimated the consequences of
disease-related events (including quality-adjusted life-
years [QALYs] and economic costs) over 35 years
(thereby encompassing the patient’s lifetime). We
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Figure 1 Bubble diagram of Markov model states and possible transitions.
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evaluated alternative scenarios to the base case involv-
ing different assumptions regarding the duration of
effects of exemestane and length of the model horizon.
Model Parameters and Data Sources
Model parameters and corresponding data sources are
summarized in Table 1 and described below.
Disease-related events. Kaplan–Meier time-to-event
analyses were performed using the maximum
48-month follow-up data (data on ﬁle, Pﬁzer, Inc.)
from the IES [6]. These analyses were used to derive
6-month transition probabilities for local and distant
recurrence and contralateral breast cancer for tamox-
ifen patients, and corresponding hazard ratios for
patients who were switched to exemestane. It was
assumed that these rates are constant over time beyond
year 4 after the switching decision; thus, an exponen-
tial distribution was employed to extend the data
an additional 6 years. Disease-related events were
assumed to occur only in the ﬁrst 10 years of the
model.
Treatment-related events. In the IES, exemestane was
associated with an increased risk of osteoporosis [6],
and tamoxifen is a known risk factor for endometrial
cancer [10]. We used the 48-month data from the IES
to generate Kaplan–Meier time-to-event curves (and
from these, 6-month probabilities) for osteoporosis
and endometrial cancer for tamoxifen patients as
well as corresponding hazard ratios for exemestane
patients. In these analyses, we excluded patients who
had osteoporosis upon entering the IES from the
at-risk pool. Because the occurrence of endometrial
cancer was rare and the hazard ratio for exemestane
did not differ signiﬁcantly from unity, in base-case
analyses we conservatively assumed no difference
between treatment strategies in the 6-month probabil-
ity of endometrial cancer.
Survival after disease-related events. Data on survival
after local and distant recurrence and contralateral
breast cancer were derived from analyses we under-
took of the SEER-Medicare database, which links the
Surveillance Epidemiology and End Results (SEER)
cancer registry with health-care claims from the Medi-
care 5% sample [11]. The SEER-Medicare data sets
obtained for this study included 12 calendar years
from 1991 to 2002. Patients who experienced a
disease-related event were identiﬁed from the SEER-
Medicare database using a methodology similar to that
of Earle et al. [12]. Kaplan–Meier time-to-event analy-
ses were used to calculate 6-month transition prob-
abilities for death after the event. It was assumed that
patients who survive 10 years after an event experience
mortality risks as in the general population, estimated
using data from published life tables [13].
Costs. Drug acquisition costs for tamoxifen and
exemestane were estimated from lowest published
US average wholesale prices [14]. Patients receiving
exemestane were assumed to receive annual dual x-ray
absorptiometry (DXA) bone density scans to monitor
for osteoporosis. The expected 10-year costs of treating
local and distant recurrences and contralateral breast
cancers were estimated from an analysis of the SEER-
Medicare database [15]. In the base-case analysis, the
10-year discounted costs of these events were assigned
to the cycle in which they occurred. In scenarios limited
to 10 years of follow-up, these costs were truncated
based on the proximity of the event to the 10-year
cutoff (e.g., an event occurring in year 7 would incur
only the ﬁrst 3 years of treatment costs). Costs of
treating endometrial cancer were derived from the pub-
lished literature [16] and were applied as a lump
sum in the cycle of onset. Costs associated with
osteoporosis—including pharmacologic therapy and
fracture treatment—were also derived from the pub-
lished literature [17], and were applied as annual costs
from the cycle of onset throughout the patient’s remain-
ing lifetime. All costs are expressed in 2004 US dollars
and were updated using the medical-care component of
the US Consumer Price Index, where necessary.
Health-related quality of life. To estimate the number
of QALYs associated with each treatment, utilities
were assigned to the various health states in the model.
A baseline utility for women aged 60 to 79 years was
used in the model to reﬂect background morbidity in
these patients, consistent with current recommenda-
tions [18]; the utility value (equal to 0.793) was
derived from nationally representative values for the
US population [19]. Published studies of utility among
women with early-stage breast cancer [20,21] were
multiplied by the baseline utility to derive values used
in our model. Utilities associated with endometrial
cancer and osteoporosis was derived from published
sources [22,23]. Osteoporosis was assumed to affect
quality of life for the lifetime of the patient. Utilities for
health states involving two or more conditions (e.g.,
local recurrence with osteoporosis) were combined in a
multiplicative fashion.
Discount rate. All costs and QALYs were discounted
to the beginning of the model using a discount rate of
3% per annum [18].
Analyses
Base-case analyses. Cumulative numbers of disease-
free months, life-years, and QALYs were calculated
over patient lifetimes from the decision to switch to
exemestane or stay on tamoxifen. These were used
along with estimates of expected lifetime costs to
estimate the incremental cost per disease-free month,
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Table 1 Model parameters, base-case inputs, and data sources
Model parameter
ER status
Data sourcePositive or unknown Positive only
Disease-related events: ﬁrst 4 years
Local recurrence (6-month probability) 0.0042 0.0040 Unpublished analyses of follow-up data from the IES
Hazard ratio associated with exemestane 0.7600 0.5958 Unpublished analyses of follow-up data from the IES
Distant recurrence (6-month probability) 0.0165 0.0156 Unpublished analyses of follow-up data from the IES
Hazard ratio associated with exemestane 0.7000 0.6518 Unpublished analyses of follow-up data from the IES
Contralateral recurrence (6-month probability) 0.0020 0.0022 Unpublished analyses of follow-up data from the IES
Hazard ratio associated with exemestane 0.3200 0.2176 Unpublished analyses of follow-up data from the IES
Disease-related events: 5–10 years
Local recurrence (6-month probability) 0.0042 0.0040 Assumption; 6-month risk of recurrence remains the
same as ﬁrst 4 years
Hazard ratio associated with exemestane 1.0000 1.0000 Assumption; exemestane and tamoxifen patients have
equivalent risks
Distant recurrence (6-month probability) 0.0165 0.0156 Assumption; 6-month risk of recurrence remains the
same as ﬁrst 4 years
Hazard ratio associated with exemestane 1.0000 1.0000 Assumption; exemestane and tamoxifen patients have
equivalent risks
Contralateral recurrence (6-month probability) 0.0020 0.0022 Assumption; 6-month risk of recurrence remains the
same as ﬁrst 4 years
Hazard ratio associated with exemestane 1.0000 1.0000 Assumption; exemestane and tamoxifen patients have
equivalent risks
Treatment-related events: ﬁrst 4 years
Osteoporosis (6-month probability) 0.0068 0.0070 Unpublished analyses of follow-up data from the IES
Hazard ratio associated with exemestane 1.4934 1.5578 Unpublished analyses of follow-up data from the IES
Endometrial cancer (6-month probability) 0.0008 0.0008 Unpublished analyses of follow-up data from the IES
Hazard ratio associated with exemestane 1.0000 1.0000 Unpublished analyses of follow-up data from the IES
Treatment-related events: 5–10 years
Osteoporosis (6-month probability) 0.0068 0.0070 Assumption; 6-month risk of osteoporosis remains
the same as ﬁrst 4 years
Hazard ratio associated with exemestane 1.0000 1.0000 Assumption; exemestane and tamoxifen patients have
equivalent risks
Endometrial cancer (6-month probability) 0.0008 0.0008 Assumption; 6-month risk of cancer remains the
same as ﬁrst 4 years
Hazard ratio associated with exemestane 1.0000 1.0000 Assumption; exemestane and tamoxifen patients have
equivalent risks
Probability of breast cancer death after disease-related events
Death after local recurrence (6-month probability)
Within 30 months of recurrence 0.0861 0.0883 Stokes, in press [15]
More than 30 months since recurrence 0.0226 0.0238 Stokes, in press [15]
Death after distant recurrence (6-month probability)
Within 6 months of recurrence 0.4491 0.4228 Stokes, in press [15]
7–30 months since recurrence 0.1966 0.2030 Stokes, in press [15]
31–60 months since recurrence 0.0792 0.0976 Stokes, in press [15]
More than 60 months since recurrence 0.0138 0.0275 Stokes, in press [15]
Death after contralateral cancer (6-month probability) 0.0107 0.0114 Stokes, in press [15]
Utilities
Baseline utility for women aged 60–79 —— 0.793 —— Hanmer 2006 [19]
Breast cancer (no recurrence) —— 0.769 —— Hanmer 2006 [19]; Delea 2006 [21]
Local recurrence
First year —— 0.611 —— Hanmer 2006 [19]; Delea 2006 [21]
Thereafter —— 0.769 —— Hanmer 2006 [19]; Delea 2006 [21]
Distant recurrence —— 0.515 —— Hanmer 2006 [19]; Delea 2006 [21]
Contralateral cancer
First year —— 0.611 —— Hanmer 2006 [19]; Delea 2006 [21]
Thereafter —— 0.769 —— Hanmer 2006 [19]; Delea 2006 [21]
Endometrial cancer —— 0.699 —— Hanmer 2006 [19];Armstrong 2001 [23]
Osteoporosis —— 0.746 —— Oleksik et al. 2002 [22]; Delea 2006 [21]
Death —— 0 —— By deﬁnition
Costs (2004$)
Tamoxifen (daily) —— 2.84 —— Drug Topics RedBook, 2004 [14]
Exemestane (daily) —— 8.09 —— Drug Topics RedBook, 2004 [14]
Monitoring hormone therapy, exemestane (annual) —— 128.23 —— 2004 National Physician Fee Schedule Relative Value
File (CMS 2004) for DXA bone density study
(CPT 76075), assumed to occur annually
Treatment of:
Local recurrence 20,558 20,879 Stokes, in press [15]
Distant recurrence 11,947 13,627 Stokes, in press [15]
Contralateral cancer 19,915 20,839 Stokes, in press [15]
Treatment of endometrial cancer (total cost) —— 21,254 —— Barnes 1999 [16]
Treatment of osteoporosis (annual cost) —— 871 —— Orsini 2005 [17]
Discount rate —— 0.03 —— Gold 1996 [18]
ER, estrogen receptor; IES, Intergroup Exemestane Study.
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life-year saved, and QALY gained, respectively. Main
analyses were performed for patients with positive
or unknown ER status; a subgroup analysis was
performed for patients with tumors known to be
ER-positive. All analyses were performed from the
societal perspective, as deﬁned by the US Panel on
Cost-Effectiveness in Health and Medicine, with pro-
ductivity losses assumed to be reﬂected in the utility
weights and therefore excluded from the cost calcula-
tions [18]. We excluded patient time and travel costs
from consideration because we assumed these would
be relatively small and unlikely to differ between the
two treatment strategies.
Probabilistic sensitivity analyses. To assess parameter
uncertainty in the cost-effectiveness analysis, probabi-
listic sensitivity analyses were performed. Distribu-
tions for probabilities of disease-related events, death,
and osteoporosis, as well as for costs of disease-related
events were derived by nonparametric bootstrapping
of patient populations in the IES and SEER-Medicare
databases. Bootstrapping involves randomly
“drawing” (with replacement) treatment populations
from within their respective treatment groups, preserv-
ing the original sample size of each group [24]. This
process of drawing populations and running the model
was repeated 1000 times, which is equivalent to 1000
different IES trials and SEER-Medicare samples.
Results of the probabilistic analysis were used to con-
struct 95% conﬁdence intervals (CIs) around the incre-
mental cost-effectiveness ratio, and were depicted
graphically as a joint distribution of incremental costs
and QALYs as well as a cost-effectiveness acceptability
curve showing the probability that the switch-to-
exemestane strategy is cost-effective at varying cost-
per-QALY thresholds.
Deterministic sensitivity analyses. To assess the
robustness of our ﬁndings to variations in individual
model parameters, one-way sensitivity analyses were
performed by varying key model parameters through
plausible ranges and examining the effects on the cost-
effectiveness ratio. Plausible ranges of parameter esti-
mates were identiﬁed as the base-case value  two
standard errors calculated from the bootstrap analysis
or the base-case value  25% for other model param-
eters. The sensitivity of our results to the discount
factor was assessed by running the model undis-
counted and at a discount rate of 5% per annum.
In addition, although current guidelines do not
provide speciﬁc recommendations for prophylaxis
[25], the risk of osteopenia may lead some clinicians to
prescribe bone-preserving therapy at the time of
switching patients to an aromatase inhibitor. We
accordingly conducted a sensitivity analysis in which
we arbitrarily assumed that one-half of all exemestane
patients would receive bisphosphonate therapy
throughout the period of exemestane treatment; in this
analysis, we assumed that the cost of bisphosphonate
therapy was $957 annually, based on an estimate
reported in a recently published cost-effectiveness
analysis of alendronate in osteopenic women [26].
To assess the impact of our reliance on the IES data,
and to provide external validation of our model results,
we conducted another sensitivity analysis in which we
utilized published data on breast cancer recurrence as
an alternative to extrapolating the IES data beyond
4 years. A multitude of other trials have evaluated the
effects of a 5-year course of tamoxifen on the risks of
breast cancer recurrence, and the Early Breast Cancer
Trialists’ Collaborative Group has conducted meta-
analyses of these trials to report pooled rates for up to
15 years after initiation of therapy [3]. We used rates
reported at years 5 and 15 (15.1% and 33.2%, respec-
tively) for women with ER-positive or ER-unknown
disease to compute 6-month risks, which we then
inserted into our model to project recurrence risks for
years 5 to 10. As in base-case analyses, we conserva-
tively assumed that the risks of breast cancer recurrence
would be equivalent between tamoxifen and exemes-
tane patients during this period (i.e., exemestane
confers no treatment beneﬁt beyond year 4).
Alternate scenarios. Because it is unknown whether
the clinical effects of exemestane in terms of reducing
recurrence risks and increasing osteoporosis risk
would persist beyond the 4-year period for which we
had data, we conducted analyses for an alternate sce-
nario in which these effects would continue for
10 years. In this scenario, we retained the lifetime
horizon for the model (“Ten-Year Effects/Lifetime
Model Horizon” scenario). Since some decision-
makers may be interested in analyses that have not
been extrapolated over the patient’s lifetime, we evalu-
ated another alternate scenario in which we limited the
model horizon to 10 years. In this scenario, we
retained our base-case assumption that the effects of
exemestane would be limited to 4 years (“Four-Year
Effects/Ten-Year Model Horizon” scenario).
Results
Base-Case Scenario
Switching to exemestane after 2 to 3 years of therapy
with tamoxifen is estimated to yield nine additional
months of disease-free survival (181 vs. 172), 0.48
life-years saved (16.62 vs. 16.14), and 0.32 QALYs
gained (12.21 vs. 11.89) per patient versus an alterna-
tive strategy of remaining on tamoxifen. Discounted
gains are seven additional disease-free months, 0.33
life-years saved, and 0.22 QALYs gained per pati-
ent (Table 2). Lifetime discounted total costs of
breast cancer prevention and related health events are
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estimated to be $4400 higher per patient for those
switched to exemestane, reﬂecting higher costs of adju-
vant hormone therapy ($6731 vs. $2321), monitoring
($293 vs. $0), and osteoporosis treatment ($1115 vs.
$872); and lower costs of treating recurrences and
contralateral cancers ($3735 vs. $4293). The incremen-
tal cost-effectiveness of switching to exemestane is esti-
mated to be $20,100 per QALY gained. Switching to
exemestane is estimated to be more cost-effective in
patients with tumors known to be ER-positive, with an
incremental cost-effectiveness ratio of $16,600 per
QALY gained.
Results of probabilistic model analyses are plotted
in the incremental cost-effectiveness plane depicted in
Figure 2. The few points to the left of the vertical axis
show that there is a very slight probability (0.4%) that
exemestane is dominated by tamoxifen (i.e., by being
both more costly and less effective). All remaining
points lie in the region where exemestane is both more
costly and more effective than tamoxifen. The ratio of
mean incremental cost to mean incremental effective-
ness for exemestane is $20,100 per QALY gained
(95% CI: $12,100, $59,000). The cost-effectiveness
acceptability curve indicates that there is a 70.5%
likelihood that exemestane is cost-effective at a thresh-
old of $25,000 per QALY and a 96.4% likelihood at a
$50,000 per QALY threshold (Fig. 3).
Systematic variation of individual model param-
eters in one-way sensitivity analyses indicates that
the model results are most sensitive to variations
in exemestane’s hazard ratio for distant recurrence,
patient utility in the no recurrence state, and the daily
cost of exemestane; and least sensitive to variations in
the probability of endometrial cancer among tamox-
ifen patients, patient utility in the ﬁrst year after recur-
rence, and the probability of contralateral breast
cancer among patients receiving tamoxifen (Table 3).
The incremental cost per QALY gained for exemestane
would be $14,700 if costs and QALYs were undis-
counted and $24,100 if discounted at a 5% annual
rate. If we assume that one-half of all patients switched
to exemestane receive bisphosphonate therapy as pro-
Table 2 Cost-effectiveness of switching to exemestane versus staying on tamoxifen in treatment of breast cancer
Treatment strategy
Total
cost* ($)
Disease-
free
months*
(DFM)
Life-
years*
(LY)
Quality-
adjusted
life-years
(QALY)*
ICER
($/DFM)
ICER
($/LY)
ICER
($/QALY)
ER-positive and
ER-unknown
Stay on tamoxifen 7,724 127.03 11.88 8.77 — — —
Switch to exemestane 12,124 133.53 12.21 8.99 680 13,300 20,100
ER-positive only
Stay on tamoxifen 7,853 128.64 11.95 8.83 — — —
Switch to exemestane 12,152 136.56 12.34 9.09 540 10,900 16,600
*Per patient, discounted at 3% per annum. For combined ER-positive and ER-unknown patients, undiscounted health outcomes were 171.61 and 180.81 recurrence-free months,
16.14 and 16.62 life-years, and 11.16 and 11.48 quality-adjusted life-years with continued tamoxifen and switching to exemestane, respectively. For ER-positive patients only,
undiscounted health outcomes were 174.02 and 185.24 recurrence-free months, 16.24 and 16.82 life-years, and 11.26 and 11.64 quality-adjusted life-years with continued
tamoxifen and switching to exemestane, respectively.
ER, estrogen receptor; ICER, incremental cost-effectiveness ratio.
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Figure 2 Bootstrap estimates of incremental costs and effectiveness for switching to exemestane versus staying on tamoxifen in treatment of breast
cancer (ER-positive & ER-unknown). QALY, quality-adjusted life-year.
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phylaxis against osteoporosis, then the incremental
cost-effectiveness ratio for exemestane would be
$25,000. Using published rates of breast cancer recur-
rence after tamoxifen to project breast cancer risks as
an alternative to extrapolating the IES data beyond
4 years yields an incremental cost-effectiveness ratio
for exemestane of $17,800.
Alternate scenarios. In the Ten-Year Effects/Lifetime
Model Horizon scenario, in which we extrapolate
hazard ratios for recurrence and osteoporosis for
exemestane patients from years 1 to 4 through years 5
to 10, the cost-effectiveness of exemestane is estimated
to be $9100 per QALY gained for all patients and
$7100 per QALY gained for ER-positive patients
(Table 4). If only the hazard ratio for osteoporosis risk
is extrapolated through years 5 to 10, the correspond-
ing cost-effectiveness ratios are estimated to be
$26,500 and $21,900, respectively (data not shown).
In the Four-Year Effects/Ten-Year Model Horizon sce-
nario, in which we reduce the model horizon from
lifetime to 10 years, the incremental cost-effectiveness
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Figure 3 Cost-effectiveness acceptability cur-
ve depicting probability that switching to
exemestane is cost-effective versus staying on
tamoxifen at alternative thresholds (ER-positive
& ER-unknown).QALY,quality-adjusted life-year.
Table 3 One-way sensitivity analysis of cost-effectiveness model parameters for exemestane versus tamoxifen (ER-positive and
ER-unknown patients)
Parameter Base case
Low % of
base case
High % of
base case
Low ICER
($/QALY)
High ICER
($/QALY)
Magnitude of
variation in ICER
Distant recurrence
Hazard ratio for exemestane 0.700 78 122 12,300 44,400 32,100
Tamoxifen probability of recurrence 0.016 87 113 17,700 22,200 4,500
Utility*† 0.515 75 125 19,200 21,000 1,300
Expected lifetime cost of treatment $11,947 63 137 19,000 20,100 1,000
Local recurrence
Hazard ratio for exemestane 0.760 58 142 16,400 24,000 7,600
Tamoxifen probability of recurrence 0.004 74 126 19,200 20,100 900
Utility after remission*† 0.769 75 118 19,500 20,700 700
Expected lifetime cost of treatment $20,558 81 119 19,500 19,700 200
Utility in ﬁrst year after recurrence*† 0.611 75 125 20,000 20,100 100
Contralateral breast cancer
Utility after remission*† 0.769 75 100 18,600 21,800 1,300
Expected lifetime cost $19,915 56 144 19,300 19,900 600
Hazard ratio for exemestane 0.320 11 189 19,400 19,800 400
Tamoxifen probability of contralateral cancer 0.002 62 138 19,500 19,700 200
Utility in ﬁrst year after recurrence*† 0.611 75 113 19,900 20,200 200
Other parameters
Base utility*† 0.793 75 125 16,000 26,700 19,900
Daily cost of exemestane* $8.09 75 125 12,100 27,100 15,000
Exemestane hazard ratio for osteoporosis 1.493 70 130 16,200 24,200 8,000
Daily cost of tamoxifen* $2.84 75 125 17,000 22,200 5,200
Tamoxifen probability of osteoporosis 0.007 79 121 18,700 20,600 1,900
Exemestane annual monitoring cost* $128 75 125 19,300 19,900 600
Exemestane hazard ratio for endometrial cancer* 1.000 75 125 19,400 19,800 400
Tamoxifen probability of endometrial cancer 0.001 38 162 19,600 19,600 40
*Ranges estimated as 25% of model values.
†Range for parameter bound by deﬁnition or by other model parameters.
Note: Ranges for parameters equal to 2 standard errors calculated in bootstrap analysis, unless otherwise speciﬁed.
ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life-year.
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ratios for exemestane are estimated to be $38,200 for
all patients and $32,000 for ER-positive patients.
Discussion
The results of our analysis suggest that the switch-to-
exemestane strategy represents a cost-effective use of
health-care resources, despite the fact that the per-day
cost of exemestane therapy is nearly three times higher
than tamoxifen. Under base-case assumptions, the in-
cremental cost-effectiveness of switching to exemestane
is estimated to be $20,100 per QALY gained for pati-
ents with ER-positive or unknown status and $16,600
per QALY gained for ER-positive patients alone. In
analyses of alternate scenarios regarding the duration of
treatment beneﬁt and consequences of disease-related
events, the cost-effectiveness of the switch-to-
exemestane strategy was less than $39,000 per QALY
even under the most pessimistic model assumptions.
It is instructive to compare these incremental cost-
effectiveness ratios with those that have been reported
for other breast cancer screening and management
strategies [27]. For instance, the cost-effectiveness of
mammography screening versus no screening among
45- to 69-year-old women was reported to be $18,000
per QALY gained; the cost-effectiveness of screening
every 1.3 years among 40- to 70-year-old women
versus biennial screenings among 50- to 70-year-old
women was $140,000 per QALY gained. The cost-
effectiveness of breast conserving surgery versus modi-
ﬁed radical mastectomy for women with stages I–II
breast cancer was $21,000. For adjuvant therapy, the
cost-effectiveness of tamoxifen has been reported to be
$5700 per QALY gained among 45-year-old premeno-
pausal women with node-positive, ER-positive breast
cancer; $15,000 per QALY gained among node-
negative, ER-positive patients; and $280,000 per
QALY gained among node-negative, ER-negative
patients. All of these cost-effectiveness ratios were
reported in 1998 US dollars—the medical-care compo-
nent of the Consumer Price Index increased 28%
between 1998 and 2004 [28], the year on which our
cost estimates are indexed. In a more recent study,
the cost-effectiveness of trastuzumab ranged from
$125,000 to $145,000 per QALY gained (2002 US
dollars) depending on the testing strategy employed
[29]. These comparisons suggest that the cost-
effectiveness of the switch-to-exemestane strategy is on
par with or better than that of many routinely used
breast cancer interventions.
Although our analysis clearly casts the switch-to-
exemestane strategy in a favorable light, for a number
of reasons our ﬁndings may be conservative. For one,
tamoxifen use has been established as a risk factor for
endometrial cancer [10]; no such association has been
reported for exemestane or other aromatase inhibitors.
Nevertheless, we conservatively assumed no excess risk
of endometrial cancer for patients staying on tamox-
ifen, and in fact the expected costs of endometrial
cancer were slightly higher for patients switching to
exemestane because of their increased life expectancy.
In addition, though tamoxifen patients may be at
increased risk of vaginal bleeding, we did not include
costs of monitoring (e.g., transvaginal ultrasonogra-
phy) or treatment of these events. Similarly, tamoxifen
use has been associatedwith an increased risk of venous
thrombosis compared with aromatase inhibitors
[30,31]. This too was conservatively excluded from the
model, though because these events are rare the effects
are likely minimal.
Using a methodological approach quite different
from ours, Lønning examined the cost-effectiveness of
the switch-to-exemestane strategy and reported cost-
effectiveness ratios similar to ours ($14,600–24,700 per
QALY for themost comparable population) [32].Other
economic evaluations of aromatase inhibitors in early-
stage breast cancer also have been reported. Hillner
used interim data from the Arimidex, Tamoxifen,
Table 4 Cost-effectiveness of switching to exemestane versus staying on tamoxifen under alternate model scenarios
Model scenario/
treatment strategy
Total cost
($)
Disease-free
months
(DFM)
Life-
years
(LY)
Quality-adjusted
life-years
(QALY)
ICER
($/DFM)
ICER
($/LY)
ICER
($/QALY)
ER-positive and ER-unknown
10-year effects/lifetime model horizon
Staying on tamoxifen 7,724 127.03 11.88 8.77 — — —
Switching to exemestane 11,694 140.06 12.53 9.20 300 6,100 9,100
4-year effects/10-year model horizon
Staying on tamoxifen 9,274 80.10 7.37 5.47 — — —
Switching to exemestane 13,553 83.71 7.54 5.58 1,190 26,100 38,200
ER-positive only
10-year effects/lifetime model horizon
Staying on tamoxifen 7,858 128.64 11.95 8.83 — — —
Switching to exemestane 11,545 144.66 12.74 9.35 230 4,700 7,100
4-year effects/10-year model horizon
Staying on tamoxifen 9,467 80.79 7.41 5.50 — — —
Switching to exemestane 13,623 85.16 7.60 5.63 950 21,700 32,000
ER, estrogen receptor; ICER, incremental cost-effectiveness ratio.
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Alone, or in Combination (ATAC) trial to evaluate the
cost-effectiveness of adjuvant therapy with anastrozole
versus tamoxifen, reporting the incremental cost-
effectiveness of anastrozole to be $89,000 per QALY
gained [33]. Locker et al. also used ATAC trial data to
estimate the cost-effectiveness of anastrozole versus
tamoxifen; focusing on ER-positive patients, they
reported a cost-effectiveness ratio of $23,740 [34].
Sorensen and Locker, using ATAC trial data
with a focus on HR-positive patients, reported the
incremental cost-effectiveness of anastrozole compared
with tamoxifen to be $25,170 per life-year gained [20].
Delea et al. assessed the cost-effectiveness of using letro-
zole after the 5-year tamoxifen regimen based on the
results of MA-17, ﬁnding this strategy to cost $28,730
per QALY gained versus no further adjuvant therapy
[21]. Caution should be exercised in comparing results
across these studies, as differences exist in modeling
approach as well as in study design, patient selection
criteria, and length of follow-up of the clinical trials on
which the economic models were based.
Some important limitations of our study should
be noted. For one, because the IES data available to
us encompassed a maximum follow-up period of
48 months, we used modeling techniques to extrapo-
late rates of breast cancer recurrence out to 10 years.
We chose a 10-year period because available data
suggest that patients who received a 5-year course of
tamoxifen treatment remain at risk of experiencing
recurrence during this time [3]; because no comparable
data exist for exemestane, we conservatively assumed
that patients switched to exemestane would have rates
of recurrence in years 5 to 10 identical to patients who
stayed on tamoxifen. We note also that, in clinical
practice, patients who follow the stay-on-tamoxifen
strategy would be eligible for aromatase inhibitor
therapy after completion of the 5-year tamoxifen
regimen, based on evidence from the MA-17 study that
use of letrozole in this fashion prevents recurrence [8]
and represents a cost-effective use of health-care
resources [34]. Incorporating this scenario into our
cost-effectiveness analysis was beyond the scope of our
study. Future research may shed light on the optimal
timing and choice of aromatase inhibitor therapy in
early-stage breast cancer.
A review of the literature conducted at the time we
designed our study indicated that data on resource
utilization after breast cancer-related events were
limited. In addition, such data were not collected in the
IES, nor was the period of follow-up in the trial sufﬁ-
ciently long to assess implications for overall survival.
We therefore conducted analyses of the SEER-
Medicare database to assess survival and costs among
early-stage breast cancer patients who experienced
recurrence or contralateral cancers [15]. The SEER-
Medicare database is limited to patients aged 65 years
or more, which limits the generalizability of these data
to younger patients. In our analyses of post-event sur-
vival, we adjusted for the difference in age between
patients in SEER-Medicare versus those enrolled in the
IES using data from standard US life tables. Neverthe-
less, our analyses of post-event treatment costs were
not adjusted for age. Therefore, if treatment of disease-
related events differs markedly among postmenopausal
women younger versus older than 65 years of age, our
estimates of post-event costs may be less valid.
A prior clinical decision analysis reported that
switching to an aromatase inhibitor midway through
the standard 5-year regimen of tamoxifen therapy
yields larger gains in disease-free survival over 10 years
than other adjuvant hormonal treatment strategies
involving tamoxifen and/or an aromatase inhibitor
[35]. The results of our analyses of exemestane versus
tamoxifen suggest that this switching strategy also con-
stitutes a cost-effective use of health-care resources,
comparing favorably with routine mammography
screening. Increases in the daily cost of adjuvant hor-
mone therapy associated with exemestane are partially
offset by reduced costs of breast cancer-related events,
and the remaining cost increment yields gains in
quality-adjusted survival at a net cost that is lower than
many commonly used cancer treatments and within ac-
cepted thresholds for medical interventions in general.
Source of ﬁnancial support: Pﬁzer Inc., New York, NY, USA.
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